Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Jaguar Health Inc (NQ: JAGX )

1.100 -0.100 (-8.33%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Jaguar Health Inc

< Previous 1 2 3 4 5 6 7 8 9 Next >
Jaguar Health Announces the Presentation of Findings from the Investigator-Initiated Phase 2 HALT-D Study of Crofelemer for Prevention of Chemotherapy-Induced Diarrhea (CID) in Breast Cancer Patients at San Antonio Breast Cancer Symposium (SABCS 2021)
Results of the study provide the first proof-of-concept data for potential use of crofelemer - a novel, oral, plant-based, non-opioid antidiarrheal prescription medication - in breast cancer patients... 
From Jaguar Health, Inc.
Via AccessWire
Exposures Product Safety
Jaguar Health to Host Scientific Discussion about Cancer Therapy-Related Diarrhea in Breast Cancer and the Company’s Ongoing OnTarget Pivotal Phase 3 Trial at San Antonio Breast Cancer Symposium (SABCS 2021)
Content from the discussion will be featured in upcoming "Diarrhea Dialogues: Part 2" SAN FRANCISCO, CA / ACCESSWIRE / December 6, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced it is hosting... 
From Jaguar Health, Inc.
Via AccessWire
Exposures Product Safety
Jaguar Health Announces Topline Results of Investigator-Initiated Phase 2 Study of Crofelemer for Prevention of Chemotherapy-Induced Diarrhea (CID) in Breast Cancer Patients
Crofelemer is a novel, oral plant-based non-opioid antidiarrheal medication SAN FRANCISCO, CA / ACCESSWIRE / November 19, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced topline results of the... 
From Jaguar Health, Inc.
Via AccessWire
Exposures Product Safety
Jaguar Health Reports 2021 Third Quarter Financial Results
Mytesi® prescription volume increased 7.6% in Q3 2021 over Q2 2021 Third quarter 2021 Mytesi net and gross sales were approximately $0.6 million and approximately $3.2 million Company expects to... 
From Jaguar Health, Inc.
Via AccessWire
Topics Regulatory Compliance
Exposures Legal Product Safety Regulatory
Jaguar Health's Italian Subsidiary Napo EU Appoints Massimo Mineo General Manager
REMINDER: Jaguar to host investor webcast Wednesday, November 17th at 8:30 a.m. Eastern regarding third quarter 2021 financials & business updates; Click here to register for webcast SAN FRANCISCO, CA... 
From Jaguar Health, Inc.
Via AccessWire
Exposures Product Safety
Jaguar Health Investor Webcast Rescheduled for Wednesday, November 17th at 8:30 AM Eastern Time
Click here to register for webcast Company plans to file Q3 2021 10-Q on November 17, 2021 SAN FRANCISCO, CA / ACCESSWIRE / November 15, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that... 
From Jaguar Health, Inc.
Via AccessWire
Exposures Product Safety
Jaguar Health to Host Investor Webcast Monday, November 15th at 8:30 AM Eastern Time Regarding Q3 2021 Financials & Business Updates
Click here to register for webcast Company plans to file Q3 2021 10-Q on November 15, 2021 SAN FRANCISCO, CA / ACCESSWIRE / November 10, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that... 
From Jaguar Health, Inc.
Via AccessWire
Exposures Product Safety
Jaguar Health's Italian Subsidiary Napo EU Appoints Annabella Amatulli Chief Regulatory Officer
SAN FRANCISCO, CA / ACCESSWIRE / November 8, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced the appointment by Napo EU S.p.A., the company's Italian subsidiary, of Annabella Amatulli as chief... 
From Jaguar Health, Inc.
Via AccessWire
Exposures COVID-19 Product Safety
Jaguar Health Completes Filing of New Animal Drug Application for Conditional Approval of Canalevia-CA1 (Crofelemer) to Treat Chemotherapy-Induced Diarrhea in Dogs, Clearing Way for December 2021 Launch
Canalevia™-CA1 is the first and only oral plant-based prescription drug candidate for CID in dogs Jaguar kicks off educational awareness contest in honor of International Jaguar Day; Click here to... 
From Jaguar Health, Inc.
Via AccessWire
The Merger of Dragon SPAC S.p.A. and Napo EU S.p.A. has Closed
The combined entity is named Napo EU S.p.A. SAN FRANCISCO, CA / ACCESSWIRE / November 1, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that the merger of its Italian subsidiary Napo EU... 
From Jaguar Health, Inc.
Via AccessWire
Exposures Product Safety
Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, CA / ACCESSWIRE / October 29, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") announced today that, effective October 25, 2021, the Company granted nonstatutory... 
From Jaguar Health, Inc.
Via AccessWire
Exposures Product Safety
Italian Government Clears Merger Plan of Dragon SPAC S.p.A. and Jaguar Health's Italian Subsidiary Napo EU S.p.A. for Closing
Merger expected to be effective within a week The combined entity will be named Napo EU S.p.A. Merger effects the exclusive license agreement between Jaguar and Napo EU S.p.A. including up-front... 
From Jaguar Health, Inc.
Via AccessWire
Exposures Product Safety
Jaguar Health Provides Updates on Crofelemer and Lechlemer Development Pipeline as well as Merger of Napo EU S.p.A. and Dragon SPAC S.p.A.
Dragon SPAC and Jaguar subsidiary Napo EU submit required notification to the Italian government in support of consummating the merger Results accepted for third-party, investigator-initiated Phase 2... 
From Jaguar Health, Inc.
Via AccessWire
Exposures Product Safety
Jaguar Health's Founder and CEO Lisa Conte to Be Honored with Pure Earth Impact Award
Award celebrates Ms. Conte's 30-year, unrelenting commitment to supporting Indigenous communities in the Amazon and responsibly harvesting and commercializing the first-ever plant-based oral medicine... 
From Jaguar Health, Inc.
Via AccessWire
Topics Death
Exposures Death Product Safety
Jaguar Health Announces that Ladenburg Thalmann is Hosting R&D Showcase Webinar About Cancer Therapy-related Diarrhea on September 29, 2021
Leading oncologists discuss importance of supportive care for cancer patients to address debilitating diarrhea resulting from cancer therapy Virtual event 1:00 PM to 2:10 PM Eastern Registration open... 
From Jaguar Health, Inc.
Via AccessWire
Jaguar Health Receives "Complete" Letter from FDA for Last of Four Major Technical Sections for the Company's Application for Conditional Approval of Canalevia (Crofelemer) for Chemotherapy-Induced Diarrhea (CID) in Dogs
Jaguar planning for launch of Canalevia™ for CID in dogs this December Canalevia is the first and only oral plant-based prescription drug candidate for CID in dogs SAN FRANCISCO, CA / ACCESSWIRE /... 
From Jaguar Health, Inc.
Via AccessWire
Exposures Product Safety
REMINDER: Jaguar Health to Host Investor Webcast Monday, September 20th at 8:30 AM Eastern Time
Click here to register for webcast Jaguar kicks off educational awareness contest in honor of Indigenous Peoples' Day; Click here to enter SAN FRANCISCO, CA / ACCESSWIRE / September 16, 2021 / Jaguar... 
From Jaguar Health, Inc.
Via AccessWire
Exposures Product Safety
Orphan Drug Designation Application Submitted by Jaguar Health Subsidiary for Crofelemer for Short Bowel Syndrome with Intestinal Failure Accepted for Review by European Medicines Agency
The conditional marketing authorization pathway in Europe for crofelemer for this orphan disease is the initial focus of Napo EU under the license agreement between Napo EU and Napo Pharmaceuticals... 
From Jaguar Health, Inc.
Via AccessWire
Exposures Product Safety
Jaguar Health Announces Closing of Private Placement Priced at a Premium to Market
Participating investors include Jaguar CEO and CFO, Dragon SPAC S.p.A. sponsor Josh Mailman, and plant-based pharmaceutical manufacturing pioneer Indena S.p.A. Company to host investor webcast Monday,... 
From Jaguar Health, Inc.
Via AccessWire
Topics Regulatory Compliance
Exposures Legal Product Safety Regulatory
Jaguar Health Appoints Karen Brunke, Ph.D. as Corporate and Business Development EVP and Chip Whitlow as Animal Health Products Marketing Director
Appointments represent Jaguar's focus on forging business development partnerships to advance crofelemer development and access and preparing for the expected near-term approval and commercialization... 
From Jaguar Health, Inc.
Via AccessWire
Exposures Product Safety
Jaguar Health, Inc. Announces 1-for-3 Reverse Stock Split
- Reverse split approved by majority of common stock shareholders at December 2020 special meeting of stockholders - Shares of Jaguar common stock to begin trading on split-adjusted basis on September... 
From Jaguar Health, Inc.
Via AccessWire
Topics Regulatory Compliance
Exposures Legal Product Safety Regulatory
Jaguar Health Reports Voting Results from 2021 Annual Meeting of Stockholders
Proposals 1, 2, 4, 5 & 6 approved SAN FRANCISCO, CA / ACCESSWIRE / September 3, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced the voting results of the Company's... 
From Jaguar Health, Inc.
Via AccessWire
Topics Regulatory Compliance
Exposures Legal Product Safety Regulatory
Jaguar Health Subsidiary Napo Pharmaceuticals Submits Late-Breaking Abstract for Consideration for Presentation at the 2021 IDWeek Annual Meeting
Exploratory study evaluating effects of crofelemer on gut microbiome SAN FRANCISCO, CA / ACCESSWIRE / August 23, 2021 / Napo Pharmaceuticals, the wholly-owned subsidiary of Jaguar Health, Inc.... 
From Jaguar Health, Inc.
Via AccessWire
Exposures Product Safety
Jaguar Health Subsidiary Napo Pharmaceuticals Signs License Agreement with its Italian Subsidiary, Napo EU S.p.A., to Develop and Commercialize Crofelemer and Lechlemer in Europe
Per the terms of the agreement, Napo Pharmaceuticals will receive an upfront payment of $10 million payable in two installments following the anticipated merger of Napo EU and Dragon SPAC S.p.A. and is... 
From Jaguar Health, Inc.
Via AccessWire
Exposures Product Safety
Jaguar Health Subsidiary Announces Completion of Additional Preclinical Study of Lechlemer (NP-300), the Company's Human Drug Product Candidate for Diarrhea Relief from Cholera and Other Acute Infectious Diarrhea
In support of planned Investigational New Drug application for lechlemer, Napo Pharmaceuticals, Jaguar's wholly owned subsidiary, received comprehensive animal toxicity preclinical services supported... 
From Jaguar Health, Inc.
Via AccessWire
Topics Death
Exposures Death Product Safety
Jaguar Health, Inc. Reports 2021 Second Quarter Financial Results
Second quarter 2021 Mytesi® net and gross sales were approximately $0.4 million and approximately $4.9 million Company transitioning to primarily selling Mytesi directly through selected specialty... 
From Jaguar Health, Inc.
Via AccessWire
Topics Regulatory Compliance
Exposures COVID-19 Legal Product Safety
Jaguar Health Announces Time Change for Friday, August 13th Investor Webcast to 8:00 AM Eastern Time
Registration link for webcast appears below Company plans to file Q2 2021 10-Q on August 13, 2021 SAN FRANCISCO, CA / ACCESSWIRE / August 10, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the... 
From Jaguar Health, Inc.
Via AccessWire
Exposures Product Safety
Jaguar Health to Host Investor Webcast Friday, August 13th at 8:30 AM Eastern Time Regarding Q2 2021 Financials & Business Updates
- Registration link for webcast appears below - Company plans to file Q2 2021 10-Q on August 13, 2021 - Jaguar kicks off educational awareness contest in honor of African Traditional Medicine Day SAN... 
From Jaguar Health, Inc.
Via AccessWire
Exposures Product Safety
Jaguar Health Announces Adjournment of Annual Meeting of Stockholders Until Friday, September 3, 2021 and Encourages All Shareholders to Vote
Based on a preliminary review of votes cast, over 75% have voted in favor of Proposals 2, 3, 4 & 6 Meeting scheduled to reconvene September 3, 2021 at 8:30 AM Pacific Standard Time to provide time to... 
From Jaguar Health, Inc.
Via AccessWire
Topics Regulatory Compliance
Exposures Legal Product Safety Regulatory
REMINDER FROM JAGUAR HEALTH: Innovators with Jane King Interview with Lisa Conte to Air During Jaguar Investor Webcast on Thursday, July 29, 2021 at 8:30 AM Eastern to Provide Business Updates
Registration link for webcast appears below SAN FRANCISCO, CA / ACCESSWIRE / July 28, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) issued a reminder today that an Innovators with Jane King interview of... 
From Jaguar Health, Inc.
Via AccessWire
Exposures Product Safety
< Previous 1 2 3 4 5 6 7 8 9 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.